Nasdaq Uthr News Today

United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) Director Christopher Causey sold 2,240 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $259.91, for a total value of $582,198.40. Following the transaction, the director now directly owns 4,185 shares in the company, valued at […]

United Therapeutics (NASDAQ:UTHR – Get Free Report) had its price target boosted by analysts at The Goldman Sachs Group from $218.00 to $240.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price objective would indicate a potential downside of […]

United Therapeutics (NASDAQ:UTHR – Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54, Briefing.com reports. The business had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had […]

Jackson Creek Investment Advisors LLC bought a new position in United Therapeutics Co. (NASDAQ:UTHR – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,106 shares of the biotechnology company’s stock, valued at approximately $683,000. Several other institutional […]

United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) has received an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among […]

California Public Employees Retirement System trimmed its stake in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 0.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 256,959 shares of the biotechnology company’s stock after selling 592 […]

Kendall Capital Management increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 45.1% in the 4th quarter, HoldingsChannel reports. The firm owned 4,212 shares of the biotechnology company’s stock after purchasing an additional 1,310 shares during the period. Kendall Capital Management’s holdings in United Therapeutics were worth $926,000 as of […]

Kendall Capital Management grew its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 45.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,212 shares of the biotechnology company’s stock after acquiring an additional 1,310 shares during the period. Kendall […]

United Therapeutics (NASDAQ:UTHR – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Wednesday. A number of other brokerages have also recently issued reports on UTHR. Wedbush reissued an “outperform” rating and issued a $308.00 target price on shares of United […]

Shares of United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) fell 3.4% during mid-day trading on Wednesday following insider selling activity. The company traded as low as $236.07 and last traded at $239.32. 136,394 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 400,432 shares. The stock had […]